A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
NCT03437083 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 340
Last updated 2019-01-25
Summary
The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.
Conditions
Interventions
- DRUG
-
Eribulin mesylate
intravenous infusion
Sponsors & Collaborators
-
Eisai Korea Inc.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-25
- Primary Completion
- 2018-06-30
- Completion
- 2018-06-30
Countries
- South Korea
Study Locations
More Related Trials
-
A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes
NCT03412955 ·Status: UNKNOWN ·Phase: PHASE2
-
Eribulin in mTNBC Patients
NCT04541420 ·Status: COMPLETED
-
Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients
NCT03795012 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
NCT01432886 ·Status: COMPLETED ·Phase: PHASE1
-
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
NCT01142661 ·Status: COMPLETED ·Phase: NA
-
Retroprospective Real Life Observatory of Eribulin
NCT02393287 ·Status: COMPLETED
-
Study of E7389 for Advanced or Metastatic Breast Cancer
NCT00965523 ·Status: COMPLETED ·Phase: PHASE2
-
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
NCT01463891 ·Status: COMPLETED
-
Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer
NCT02790320 ·Status: COMPLETED
-
Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
NCT04061863 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
NCT06857305 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
NCT03913234 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
NCT05530057 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
NCT03810976 ·Status: COMPLETED ·Phase: PHASE2
-
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
NCT02061085 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
NCT03078751 ·Status: COMPLETED ·Phase: PHASE2
-
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
NCT01269346 ·Status: COMPLETED ·Phase: PHASE2
-
Extended Treatment in Metastatic Breast Cancer With Eribulin
NCT02769364 ·Status: COMPLETED
-
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
NCT01439282 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
NCT04683445 ·Status: UNKNOWN
-
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
NCT03671330 ·Status: COMPLETED ·Phase: PHASE2
-
Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
NCT02443428 ·Status: COMPLETED
-
Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
NCT02263495 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
NCT05945368 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT07054190 ·Status: RECRUITING ·Phase: PHASE2